<DOC>
	<DOCNO>NCT01186640</DOCNO>
	<brief_summary>Study hypothesis : Simultaneous FMC-Alemtuzumab administration follow Alemtuzumab maintenance therapy patient T-PLL feasible , safe efficient .</brief_summary>
	<brief_title>Combined Immunochemotherapy Patients With T-Prolymphocytic Leukemia ( T-PLL )</brief_title>
	<detailed_description>As median survival time patient T-PLL le 12 month , treatment T-PLL special challenge . The overall response rate conventional chemotherapy Deoxycoformycin low ( 30 % 40 % ) , monoclonal antibody Alemtuzumab response rate 50 % 70 % achieve , duration response short . In previous trial ( T PLL 1 ) , efficacy FMC regimen ( FMC = Fludarabine , Mitoxantrone Cyclophosphamide ) test , preliminary analysis 16 patient reveal response rate 60 % FMC-polychemotherapy 83 % subsequent administration Alemtuzumab . The goal T-PLL2-protocol assess simultaneous administration FMC-polychemotherapy Alemtuzumab subsequent Alemtuzumab maintenance therapy capable improve remission rate disease-free survival time patient T-PLL .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Untreated patient Tprolymphocytic leukemia ( TPLL ) accord WHO criteria pretreated patient ( max . one previous treatment ) TPLL Age ≥ 18 year WHO performance status 02 Life expectancy &gt; 6 month CIRS score &gt; = 6 Left ventricular ejection fraction ≥50 % confirm echocardiogram perform &lt; 6 month inclusion trial end possible anthracycline contain pretreatment Adequate liver function indicate total bilirubin , AST ALT &gt; = 2 institutional ULN value , unless directly attributable TPLL Creatinine clearance &gt; = 70 ml/min calculate accord formula Cockcroft Gault Seronegativity HIV , HBV HCV confirm serological testing within 6 week prior registration Willingness fertile male female patient use highly effective contraceptive method PearlIndex &lt; 1 least six month end study treatment ( e.g . implant , injectables , oral contraceptive combination another contraceptive method , IUDs , sexual abstinence vasectomise partner ) Negative serum pregnancy test one week prior treatment ( require female patient &lt; 2 year onset menopause ) Patient 's write informed consent Clinically significant autoimmune cytopenia clinically significant hemolytic anaemia suspicion immune origin , even Coombs test negative Active secondary malignancy require treatment ( except basal cell carcinoma tumour curatively treat surgery ) Medical condition require prolong use oral corticosteroid ( &gt; 1 month ) Cerebral dysfunction , legal incapacity Any circumstance time study entry would preclude completion study require followup Active infection severe infection ( WHO 4th degree ) within last three month inclusion study Participation clinical trial study Known hypersensitivity study medication ( Fludarabine , Cyclophosphamide , Mitoxantrone Alemtuzumab ) Patients already receive 60 % recommend maximum cumulative dose anthracycline ( Epirubicine , Adriamycine Mitoxantrone ) . This maximum cumulative dose define individual substance follow : Epirubicin 900 mg/m² Daunorubicin 550 mg/m² , ( 400 mg/m² patient receive mediastinal irradiation ) Adriamycine ( Doxorubicine ) 550 mg/m² Mitoxantrone 200 mg/m² Patients already receive Fludarabine combination Cyclophosphamide Mitoxantrone Patients receive prior treatment Alemtuzumab alone combination purine analogue achieve PR last least 6 month Patients employee Sponsor ( University Cologne ) study site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>T-PLL</keyword>
	<keyword>Polychemotherapy</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Efficacy</keyword>
</DOC>